The KCCure Kidney Cancer Scientific Advisory Board is a national board made up of the world’s leading specialists, researchers and scientists dedicated to finding a cure for kidney cancer.
Hans Hammers, M.D., Ph.D., is a nationally and internationally recognized medical oncologist who focuses primarily on treating kidney cancer. Dr. Hammers’s expertise results in direct benefits for his patients, who receive access to the most advanced and promising treatment options. He is also the co-founder of KCCure and leader of our Scientific Advisory Board. Read more.
Alex Baras, MD – is a practicing pathologist specializing in genitourinary pathology with a comprehensive understanding of cellular and molecular research along with bioinformatics. Dr. Baras oversees the Precision Medicine Informatics and Bioinformatics for the Sidney Kimmel Comprehensive Cancer Center and the Molecular Diagnostics Laboratory, as well as the Oncology Tissue Services laboratory. Read more.
James Brugarolas, MD, Ph.D – is Director of the UT Southwestern Kidney Cancer Program, one of only a few of its kind in the United States, and Principal Investigator of the National Cancer Institute Specialized Program of Research Excellence (SPORE) award at UT Southwestern. In addition, to caring for patients, Dr. Brugarolas leads a busy research laboratory, where scientists are making promising advances in the understanding of how kidney cancer develops – and working to translate their discoveries into new therapies that target the disease’s molecular pathways. Read more.
Ithaar Derweesh, MD, is a board-certified urologist who subspecializes in urologic tumors and malignancies. He leads the surgical arm of UC San Diego Health’s multidisciplinary program for management of kidney cancer. Dr. Derweesh has established one of the highest volume kidney cancer surgical programs in North America. He is one of the world’s leading experts for partial nephrectomy for large renal masses, use of minimally invasive surgery in setting of locally advanced disease, and the use of targeted medication to enable kidney preserving treatments in settings where such treatment was not possible. Read more.
Daniel George, MD – is a medical oncologist at Duke Cancer Center, specializing in the care of patients with urologic cancers, mainly, kidney cancer, prostate cancer, bladder cancer and testicular cancer. He oversees a large clinical research team at Duke focused on developing therapy and improving care and outcomes for patients with urologic cancers. His work involves both interventional trials with new and emerging therapies as well as diagnostic tests and markers of cancer biology, response and outcome. He has a particular interest in immuno-oncology agents as well as targeted therapy. Read more.
John L. Gore, MD, MS, FACS, is a urologic oncologist and health services researcher. Dr. Gore received his MD from Baylor College of Medicine following which he completed his urology training at UCLA. He then received his health services research training as a Robert Wood Johnson Clinical Scholar at UCLA. Dr. Gore is currently an Associate Professor in Urology, Adjunct Associate Professor in Surgery at the University of Washington, and Affiliate Investigator at the Fred Hutchinson Cancer Research Center in Seattle, WA. He is the Surgical Director of the Kidney Cancer Program at the Seattle Cancer Care Alliance. He is pursuing a translational health services and patient-centered outcomes research program toward improving access to care, quality of life, and quality of care for urologic cancers. Read more.
Elizabeth Petri Henske, MD, runs the Henske Lab at Brigham and Women’s Hospital and Harvard Medical School in Boston. She is best known for her groundbreaking discovery that mutations in the TSC2 gene cause the sporadic form of lymphangioleiomyomatosis (LAM). This provided the foundation for pivotal clinical trials demonstrating the efficacy mammalian/mechanistic target of rapamycin (mTOR) inhibitors for the treatment of LAM. Her laboratory has also discovered that autophagy plays a critical role in the pathogenesis and therapy of LAM, leading to an ongoing clinical trial called the “SAIL” trial: Sirolimus and Autophagy Inhibition in LAM. Read More.
Eric Jonasch, MD is a Professor in the Department of Genitourinary Medical Oncology, Division of Cancer, at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. Dr. Jonasch is director of the VHL Clinical Center at the MD Anderson Cancer Center, co-Director of the MD Anderson Kidney Cancer Research Program, and is involved in tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials, and is in charge on an ongoing laboratory research effort evaluating the determinants of response and resistance to targeted therapies in renal cell carcinoma and VHL disease. Read more.
David McDermott, MD is Director of the Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, at Beth Israel Deaconess Medical Center. Dr. McDermott is the leader of the Kidney Cancer Program as well as a staff physician at Beth Israel. He serves as an Associate Professor of medicine at Harvard Medical School. Read more.
Kimryn Rathmell, MD is Director of the Division of Hematology/Oncology at the Vanderbilt Ingram Cancer Center. Dr. Rathmell’s research laboratory is focused on cancers caused by deregulation of the normal hypoxia response pathway. Her team uses clear cell renal cell carcinoma as a model system because virtually all of these tumors display disregulation of this pathway. Dr. Rathmell is also a Cornelius A. Craig Professor of Medicine and a Professor of Clinical Medicine and Cancer Biology. Read more.
Nizar Tannir, MD, FACP is the Deputy Department Chair of Genitourinanary Medical Oncology, Division of Cancer at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. His research focus in RCC is in clinical molecular characterization of non-clear cell RCC subtypes, particularly translocation RCC and renal medullary carcinoma. Design and conduct of informative, biology-driven clinical trials for clear-cell and non-clear cell. RCC Identification of circulating and tissue-based biomarkers of response to targeted agents and immune checkpoint antibodies in patients with clear-cell and non-clear cell RCC. Read more.
Martin Voss, MD – is a board-certified medical oncologist dedicated to the care of patients with genitourinary malignancies at Memorial Sloan Kettering Cancer Center. Dr. Voss’ clinical focus is the management of advanced cancers of the kidney and urinary tract. He works as part of a multidisciplinary team of surgeons, pathologists, radiation oncologists, and medical oncologists. Read more.
Please note: The material on this site is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment for a specific medical condition. You should not use information on this website to diagnose or treat a health problem or disease and should consult with a qualified healthcare provider with any questions or concerns you may have regarding your condition.